Anxiety is a normal behavioral component. When it is too frequent or appears in inappropriate contexts, it can be considered pathological. Benzodiazepines (BDZs) are drugs with clinical success in anxiety treatment. BDZs act as allosteric modulators of the γ- aminobutyric acid A receptor (GABAAR). However, these drugs cause adverse effects. Despite the therapeutic advances obtained with BDZs, the search for anxiolytics with fewer adverse effects is ongoing. Studies with monoterpene (–)-borneol [(–)-BOR] demonstrated pharmacological properties such as a partial agonist effect of GABAAR and an anticonvulsive effect. On the other hand, no work has been developed evaluating the anxiolytic/sedative potential. The objective of this study was to investigate the anxiolytic/sedative effects of (–)-BOR in animal models at doses of 25, 50, and 100 mg/kg (i.p.) and whether there was a molecular interaction with GABAAR. The anxiolytic effect of monoterpene (–)-BOR was tested on Swiss mice (25–30 g) in three anxiety models: the elevated plus maze test, the open field test, and the light-dark box test. The thiopental-induced sleep time model was a drug screen for the sedative and hypnotic activity related to GABAARs. In the molecular docking, the interaction between the GABAAR molecule and (–)-BOR was performed using the AutoDock 4.2.6 program. The results demonstrated that (–)-BOR has sedative and anxiolytic activity. The molecular docking study revealed that (–)-BOR can interact with GABAARs through hydrogen bonds.
Background/Objectives: α-Phellandrene (α-PHEL) is a monoterpene found in essential oils and is known for its antinociceptive and anti-inflammatory properties. This study investigated the antinociceptive effects of free α-PHEL and β-cyclodextrin-associated α-PHEL (α-PHEL/β-CD) in a Complete Freund’s adjuvant (CFA)-induced model of chronic inflammatory pain. Methods: Mechanical allodynia and hyperalgesia were evaluated in female Wistar rats using the von Frey and Randall–Selitto tests, respectively. Locomotor activity and motor performance were evaluated in male Swiss mice. Animals received α-PHEL (6.25–100 mg/kg) and α-PHEL/β-CD (3.12–12.5 mg/kg), as well as vehicle (2% Tween 80/0.9% saline) and dexamethasone (0.5 mg/kg, p.o.), with evaluations conducted in the von Frey test at intervals of 1 to 24 h. The antihyperalgesic effect was evaluated using α-PHEL, α-PHEL/β-CD, vehicle, and diclofenac (5 mg/kg, p.o.), with assessments in the Randall–Selitto test from 1 to 6 h. Over 10 days, the animals were treated and evaluated daily to determine the effect during repeated treatment. The involvement of the opioid pathway was assessed using naloxone, whereas the serotonergic pathway was investigated using PCPA and ketanserin in the von Frey test. Motor coordination was tested in the rotarod, and exploratory behavior was assessed in the open field. Results: α-PHEL reduced CFA-induced hyperalgesia and allodynia in both acute and chronic phases. The α-PHEL/β-CD preparation produced significant antinociceptive effects at all tested doses during repeated administration. Naloxone and 5-HT2A receptor blockade reduced the antinociceptive effect of α-PHEL, while α-PHEL and the α-PHEL/β-CD preparation did not alter locomotor activity or motor coordination. Conclusions: The α-PHEL/β-CD preparation exhibits antinociceptive activity in inflammatory pain without affecting locomotor activity or motor coordination. The findings with free α-PHEL suggest the possible contribution of opioid and serotonergic pathways to its antinociceptive effect.